AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$NTHI

CHEN THOMAS C purchased $40K of NTHI (indirect holdings)

CHEN THOMAS C (CEO) purchased 10,798 indirectly-held shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.70 ($3.60–$3.82) across 2 trades over 2026-09-11 to 2026-09-14.

Original reporting
SEC EDGAR · CHEN THOMAS C
Published Sep 16, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTHI
Neutral
low confidence
Mentioned
$NTHI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHINeutralLow
01

Why it matters

The purchase is modest and unlikely to affect market perception.

02

Market read

Minor insider activity with low trading relevance.

03

What to watch

Potential upcoming financing or partnership not reflected in the filing.

Relevance 4/10Novelty 2/10Timing: post‑market filing on 2026‑09‑15

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$NTHINeutralLow confidence
Context

CEO Chen Thomas C bought 10,798 shares for $39,999.83 via open‑market trades.

Expected impact

Minimal short‑term impact; unlikely to move price materially.

Evidence & confidence

Purchase amount (~$40K) is small relative to market cap; typical for 10b5‑1 plans.

Market effects

Sector

No immediate sector impact; insider activity is company‑specific.

Regional

Limited to US micro‑cap market where NTHI trades.

Global

None

Counterpoint

What could challenge this read

Even a small insider buy could hint undisclosed positive news.

Key entities

  • Company
    Neonc Technologies Holdings, Inc.

    Issuer of the Form 4 filing.

  • Person
    Chen Thomas C

    CEO and 10% owner of NTHI.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTHI insider trading history →

Related articles

AUG 13
$NTHIMed

Stonegate, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Stonegate Capital Partners updated coverage of NeOnc Technologies Holdings (NASDAQ: NTHI), citing 2Q26 progress for NEO100 and NEO212. NEO100 Phase 2a reported PFS at 6 months of 48.9% vs a 20% benchmark (p=0.0047), median OS 26.09 months, and no major toxicities. NeOnc plans a Type B FDA meeting; R&D rose to $2.6M from $0.7M year over year.

finanznachrichten.de4 min
AUG 12
$NTHIMed

WallStreet-PR: NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. It said six-month progression-free survival was 48.9% versus a 20% historical benchmark, with p=0.0047. Median overall survival was about 26 months, with no major toxicities. NeOnc plans an FDA meeting on next trial steps.

finanznachrichten.de4 min
AUG 12
$NTHIMedAI 8/10

NeOnc Technologies Reports Positive Topline Data Of NEO100 Phase 2a Study, Stock Up In Pre-Market

NeOnc Technologies Holdings (NTHI) reported positive topline Phase 2a results for intranasal NEO100 (NEO100-01) in IDH1-mutant Grade IV glioma or Grade III astrocytoma. In 24 patients at 1,152 mg/day, six-month progression-free survival was 48.9% vs 20% expected. Median overall survival was 26.09 months. Company plans an FDA Type B meeting and will present full safety data.

rttnews.com4 min
AUG 12
$NTHIHighAI 9/10

Why is Neonc Technologies stock surging today?

Investing.com reports Neonc Technologies Holdings Inc (NTHI) shares rose 11.3% pre-open after its Phase 2a NEO100-01 intranasal NEO100 study in Grade III/IV IDH1-mutant glioma met the primary endpoint. Six-month progression-free survival was 48.9% vs a 20% benchmark (p=0.0047) in 24 patients. Company discussed efficacy, safety, and next regulatory steps.

investing.com4 min
AUG 12
$NTHIMedAI 8/10

NeOnc Technologies stock jumps on positive glioma trial data

NeOnc Technologies Holdings (NASDAQ:NTHI) shares rose 11.7% after positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint with 6-month progression-free survival of 48.9% vs a 20% benchmark (p=0.0047). Median overall survival was 26.09 months; 86.7% were alive at six months. The company plans an FDA Type B meeting.

investing.com4 min